Do analysts recommend THAR or TVGN?

Tevogen Bio has a consensus target price of $100.00, indicating a potential upside of 1,633.10%. Given Tevogen Bio's stronger consensus rating and higher possible upside, analysts clearly believe Tevogen Bio is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher valuation and earnings, THAR or TVGN?

Tevogen Bio is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tharimmune N/A N/A -$12.20M -$3.99 N/A Tevogen Bio N/A N/A -$26.27M -$4.61 N/A

Is THAR or TVGN more profitable?

Tevogen Bio's return on equity of 0.00% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% Tevogen Bio N/A N/A -472.77%

Which has better earnings and valuation, BMEA or TVGN?

Biomea Fusion is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biomea Fusion N/A N/A -$61.80M -$0.68 N/A Tevogen Bio N/A N/A -$26.27M -$4.61 N/A

Is BMEA or TVGN more profitable?

Tevogen Bio's return on equity of 0.00% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -265.37% -103.96% Tevogen Bio N/A N/A -472.77%

Is BDTX or TVGN more profitable?

Tevogen Bio's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -30.18% -23.91% Tevogen Bio N/A N/A -472.77%

Does the media favor BDTX or TVGN?

In the previous week, Black Diamond Therapeutics and Black Diamond Therapeutics both had 1 articles in the media. Black Diamond Therapeutics' average media sentiment score of 0.68 beat Tevogen Bio's score of 0.67 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tevogen Bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tevogen Bio (TVGN) Competitors

$5.77 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$5.81 +0.04 (+0.69%)

As of 07/2/2026 04:10 PM Eastern

Compare

TVGN vs. THAR, FTLF, ATRA, BMEA, and BDTX

Should you buy Tevogen Bio stock or one of its competitors? MarketBeat compares Tevogen Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tevogen Bio include Tharimmune (THAR), FitLife Brands (FTLF), Atara Biotherapeutics (ATRA), Biomea Fusion (BMEA), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry.

How does Tevogen Bio compare to Tharimmune?

Tharimmune (NASDAQ:THAR) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Tharimmune has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

1.2% of Tharimmune shares are held by institutional investors. 6.7% of Tharimmune shares are held by company insiders. Comparatively, 70.5% of Tevogen Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Tevogen Bio has a consensus target price of $100.00, indicating a potential upside of 1,633.10%. Given Tevogen Bio's stronger consensus rating and higher possible upside, analysts clearly believe Tevogen Bio is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Tevogen Bio's return on equity of 0.00% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Tevogen Bio	N/A	N/A	-472.77%

Tevogen Bio is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A

In the previous week, Tevogen Bio had 1 more articles in the media than Tharimmune. MarketBeat recorded 1 mentions for Tevogen Bio and 0 mentions for Tharimmune. Tevogen Bio's average media sentiment score of 0.67 beat Tharimmune's score of 0.00 indicating that Tevogen Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Tharimmune	Neutral
Tevogen Bio	Positive

Summary

Tharimmune and Tevogen Bio tied by winning 6 of the 12 factors compared between the two stocks.

How does Tevogen Bio compare to FitLife Brands?

FitLife Brands (NASDAQ:FTLF) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

2.3% of FitLife Brands shares are held by institutional investors. 61.7% of FitLife Brands shares are held by company insiders. Comparatively, 70.5% of Tevogen Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

FitLife Brands currently has a consensus target price of $21.50, indicating a potential upside of 86.96%. Tevogen Bio has a consensus target price of $100.00, indicating a potential upside of 1,633.10%. Given Tevogen Bio's higher probable upside, analysts plainly believe Tevogen Bio is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

FitLife Brands has higher revenue and earnings than Tevogen Bio. Tevogen Bio is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$81.46M	1.33	$6.33M	$0.60	19.17
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A

FitLife Brands has a net margin of 6.64% compared to Tevogen Bio's net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat Tevogen Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FitLife Brands	6.64%	18.31%	8.21%
Tevogen Bio	N/A	N/A	-472.77%

FitLife Brands has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market.

In the previous week, Tevogen Bio had 1 more articles in the media than FitLife Brands. MarketBeat recorded 1 mentions for Tevogen Bio and 0 mentions for FitLife Brands. Tevogen Bio's average media sentiment score of 0.67 beat FitLife Brands' score of 0.00 indicating that Tevogen Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
FitLife Brands	Neutral
Tevogen Bio	Positive

Summary

FitLife Brands beats Tevogen Bio on 10 of the 15 factors compared between the two stocks.

How does Tevogen Bio compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

Atara Biotherapeutics currently has a consensus target price of $9.50, suggesting a potential downside of 18.45%. Tevogen Bio has a consensus target price of $100.00, suggesting a potential upside of 1,633.10%. Given Tevogen Bio's higher possible upside, analysts clearly believe Tevogen Bio is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Atara Biotherapeutics has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Tevogen Bio has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Tevogen Bio's return on equity of 0.00% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
Tevogen Bio	N/A	N/A	-472.77%

70.9% of Atara Biotherapeutics shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 70.5% of Tevogen Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Tevogen Bio had 1 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 1 mentions for Tevogen Bio and 0 mentions for Atara Biotherapeutics. Tevogen Bio's average media sentiment score of 0.67 beat Atara Biotherapeutics' score of 0.00 indicating that Tevogen Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Atara Biotherapeutics	Neutral
Tevogen Bio	Positive

Atara Biotherapeutics has higher revenue and earnings than Tevogen Bio. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.87	$32.69M	-$0.67	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A

Summary

Tevogen Bio beats Atara Biotherapeutics on 8 of the 15 factors compared between the two stocks.

How does Tevogen Bio compare to Biomea Fusion?

Biomea Fusion (NASDAQ:BMEA) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Tevogen Bio's return on equity of 0.00% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Tevogen Bio	N/A	N/A	-472.77%

Biomea Fusion is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A

Biomea Fusion presently has a consensus price target of $8.50, suggesting a potential upside of 502.84%. Tevogen Bio has a consensus price target of $100.00, suggesting a potential upside of 1,633.10%. Given Tevogen Bio's higher possible upside, analysts clearly believe Tevogen Bio is more favorable than Biomea Fusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Tevogen Bio had 1 more articles in the media than Biomea Fusion. MarketBeat recorded 1 mentions for Tevogen Bio and 0 mentions for Biomea Fusion. Tevogen Bio's average media sentiment score of 0.67 beat Biomea Fusion's score of 0.00 indicating that Tevogen Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Biomea Fusion	Neutral
Tevogen Bio	Positive

Biomea Fusion has a beta of -0.31, meaning that its stock price is 131% less volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

96.7% of Biomea Fusion shares are held by institutional investors. 10.6% of Biomea Fusion shares are held by insiders. Comparatively, 70.5% of Tevogen Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Tevogen Bio beats Biomea Fusion on 8 of the 13 factors compared between the two stocks.

How does Tevogen Bio compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Tevogen Bio's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-30.18%	-23.91%
Tevogen Bio	N/A	N/A	-472.77%

Black Diamond Therapeutics presently has a consensus target price of $9.83, indicating a potential upside of 389.22%. Tevogen Bio has a consensus target price of $100.00, indicating a potential upside of 1,633.10%. Given Tevogen Bio's higher possible upside, analysts clearly believe Tevogen Bio is more favorable than Black Diamond Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Black Diamond Therapeutics and Black Diamond Therapeutics both had 1 articles in the media. Black Diamond Therapeutics' average media sentiment score of 0.68 beat Tevogen Bio's score of 0.67 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Diamond Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tevogen Bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Black Diamond Therapeutics has a beta of 3.25, suggesting that its share price is 225% more volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Black Diamond Therapeutics has higher revenue and earnings than Tevogen Bio. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.65	$22.37M	-$0.77	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 70.5% of Tevogen Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Black Diamond Therapeutics beats Tevogen Bio on 10 of the 14 factors compared between the two stocks.

Get Tevogen Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TVGN vs. The Competition

Export

Metric	Tevogen Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$24.16M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-1.25	21.61	28.02	24.70
Price / Sales	N/A	340.22	540.55	99.42
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	-0.03	8.66	10.96	6.46
Net Income	-$26.27M	$23.81M	$3.57B	$337.01M
7 Day Performance	-17.57%	3.39%	2.12%	1.69%
1 Month Performance	-44.89%	10.81%	5.25%	3.81%
1 Year Performance	-90.73%	62.61%	33.29%	23.90%

Tevogen Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TVGN Tevogen Bio	1.9459 of 5 stars	$5.77 flat	$100.00 +1,633.1%	-90.7%	$24.16M	N/A	N/A	3	Gap Up
THAR Tharimmune	N/A	$2.78 -6.4%	N/A	+54.7%	$104.89M	N/A	N/A	2
FTLF FitLife Brands	4.5314 of 5 stars	$11.01 -0.5%	$21.50 +95.3%	-18.4%	$103.86M	$81.46M	18.23	20	Gap Down
ATRA Atara Biotherapeutics	0.6962 of 5 stars	$11.48 +2.8%	$9.50 -17.2%	+45.4%	$100.64M	$120.77M	N/A	330
BMEA Biomea Fusion	1.9466 of 5 stars	$1.47 +5.8%	$8.50 +478.2%	-14.8%	$100.50M	N/A	N/A	50	Analyst Downgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TVGN) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tevogen Bio (TVGN) Competitors

TVGN vs. THAR, FTLF, ATRA, BMEA, and BDTX

How does Tevogen Bio compare to Tharimmune?

Summary

How does Tevogen Bio compare to FitLife Brands?

Summary

How does Tevogen Bio compare to Atara Biotherapeutics?

Summary

How does Tevogen Bio compare to Biomea Fusion?

Summary

How does Tevogen Bio compare to Black Diamond Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN vs. The Competition

Tevogen Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tevogen Bio (TVGN) Competitors

TVGN vs. THAR, FTLF, ATRA, BMEA, and BDTX

How does Tevogen Bio compare to Tharimmune?

Which has more risk & volatility, THAR or TVGN?

Do insiders & institutionals believe in THAR or TVGN?

Do analysts recommend THAR or TVGN?

Is THAR or TVGN more profitable?

Which has higher valuation and earnings, THAR or TVGN?

Does the media favor THAR or TVGN?

Summary

How does Tevogen Bio compare to FitLife Brands?

Do institutionals & insiders believe in FTLF or TVGN?

Do analysts recommend FTLF or TVGN?

Which has stronger valuation & earnings, FTLF or TVGN?

Is FTLF or TVGN more profitable?

Which has more volatility and risk, FTLF or TVGN?

Does the media favor FTLF or TVGN?

Summary

How does Tevogen Bio compare to Atara Biotherapeutics?

Do analysts recommend ATRA or TVGN?

Which has more risk & volatility, ATRA or TVGN?

Is ATRA or TVGN more profitable?

Do insiders & institutionals hold more shares of ATRA or TVGN?

Does the media refer more to ATRA or TVGN?

Which has better valuation and earnings, ATRA or TVGN?

Summary

How does Tevogen Bio compare to Biomea Fusion?

Is BMEA or TVGN more profitable?

Which has better earnings and valuation, BMEA or TVGN?

Do analysts prefer BMEA or TVGN?

Does the media favor BMEA or TVGN?

Which has more risk & volatility, BMEA or TVGN?

Do insiders and institutionals have more ownership in BMEA or TVGN?

Summary

How does Tevogen Bio compare to Black Diamond Therapeutics?

Is BDTX or TVGN more profitable?

Do analysts rate BDTX or TVGN?

Does the media favor BDTX or TVGN?

Which has more risk and volatility, BDTX or TVGN?

Which has better earnings & valuation, BDTX or TVGN?

Do institutionals and insiders hold more shares of BDTX or TVGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN vs. The Competition

Tevogen Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools